Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2014-01680 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| FHCRC #9105 | |||
| 9105 | Other Identifier | Fred Hutch/University of Washington Cancer Consortium | |
| P30CA015704 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Insufficient staff
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This randomized pilot clinical trial studies a home telemonitoring device in managing the care of patients with myelodysplastic syndrome or acute myeloid leukemia after they are discharged from the hospital following chemotherapy. After treatment and hospital discharge, patients typically need extensive care to deal with the side effects of chemotherapy, keep up with medications, and obtain medical assistance. A home telemonitoring device would allow patients to monitor vital signs, symptoms, and use of medications, communicate with healthcare providers, and access educational material. A telemonitoring device may allow patients to be managed more effectively than standard outpatient care after being discharged from the hospital.
PRIMARY OBJECTIVES:
I. To determine the feasibility of home telemonitoring for adult patients following intensive induction, re-induction/salvage, or consolidation chemotherapy for myelodysplastic syndrome (MDS) or non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML).
SECONDARY OBJECTIVES:
I. To estimate the impact of the telemonitoring intervention on mortality, duration of hospital stay, use of emergency services, visits to primary care physicians and to specialists, home visits, and telephone calls ("health care resource utilization").
II. To evaluate the telemonitoring procedure in economic terms compared to usual care through a cost-effectiveness analysis.
III. To estimate the impact on the quality of life of study participating.
IV. To assess the degree of satisfaction of the patients/caregivers and health care professionals with the telemonitoring intervention.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I (CONTROL): Patients receive standard outpatient supportive care after completion of chemotherapy.
ARM II (INTERVENTION): Patients receive standard outpatient supportive care as in Arm I and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm I (standard outpatient supportive care) | Active Comparator | Patients receive standard outpatient supportive care after completion of chemotherapy. |
|
| Arm II (home telemonitoring device) | Experimental | Patients receive standard outpatient supportive care as in Arm I and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Health Telemonitoring | Device | Use home telemonitoring device |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients willing to use the in-home telemonitoring device | Exploratory, descriptive and observational methods will be used to determine enrollment and retention issues in AML/MDS patients who are discharged early after intensive chemotherapy. | Up to 4 weeks |
| Success of data transmission | Exploratory, descriptive, and observational methods will be used to determine the ability to remotely monitor this patient population. | Up to 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in patient conditions | Researchers' ability to use the transmitted data to support patients in recognizing changes in their conditions and managing the changes or getting appropriate medical assistance will be estimated between study arms using exploratory, descriptive, and observational methods. | Up to 4 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anna Halpern | Fred Hutch/University of Washington Cancer Consortium | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Quality-of-Life Assessment |
| Other |
Ancillary studies |
|
|
| Questionnaire Administration | Other | Ancillary studies |
|
| Supportive Care | Procedure | Receive standard outpatient supportive care |
|
|
| Degree of satisfaction of the patients/caregivers with the telemonitoring intervention |
Exploratory, descriptive, and observational methods will be used to estimate differences between the study arms. |
| Up to 4 weeks (at end of study period) |
| Degree of satisfaction of health care professionals with the telemonitoring intervention | Exploratory, descriptive, and observational methods will be used to estimate differences between the study arms. | Up to 4 weeks (at end of study period) |
| Quality of life (QOL) as assessed by the M.D. Anderson Symptom Inventory Core items and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 | Exploratory, descriptive, and observational methods will be used to estimate in the impact of the telemonitoring intervention on QOL. | Up to 4 weeks (at end of study period) |
| Percentage of returned surveys | Percentage of returned surveys will be measured as a feasibility outcome. | Up to 4 weeks |
| Mortality | The impact of the telemonitoring intervention on mortality compared to the control group will be estimated. | Up to 4 weeks |
| Health care resource utilization | Descriptive and observational methods will be used to estimate the impact of the telemonitoring intervention with regard to health care resource utilization, and data on rehospitalization (frequency, duration, resource use, and need for intensive care unit-level care). | Up to 4 weeks |
| ID | Term |
|---|---|
| D015470 | Leukemia, Myeloid, Acute |
| D009190 | Myelodysplastic Syndromes |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D001855 | Bone Marrow Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D010166 | Palliative Care |
| ID | Term |
|---|---|
| D005791 | Patient Care |
| D013812 | Therapeutics |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided